DrugDev Selected for TransCelerate's Investigator Registry
TransCelerate BioPharma Inc. has selected DrugDev to develop and host its Investigator Registry
TransCelerate BioPharma Inc. has selected DrugDev to develop and host its Investigator Registry, which will allow TransCelerate member companies to pool investigator data together into a centralized, cloud-based resource utilizing a universal identifier known as the DrugDev Golden Number. The registry, along with TransCelerate’s Shared Investigator Platform, will help streamline some of the more inefficient clinical trial processes by offering the ability to expeditiously find investigator matches for their trials will drive improved performance.
For investigators, the registry expands their access to clinical trial opportunities by making them known throughout participating TransCelerate Member Companies. Moreover, making their investigator and site profile information available in the registry reduces the number of basic site information requests, which in turn allows them to spend more time focused on clinical activities.
DrugDev also is the third party host of the Investigator Databank.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
